ライフサイエンスコーパス: Fc

1 Fc engineering enhances avidity and direct cell killing

2 Fc gamma receptors (FcgammaRs) translate antigen recogni

3 Fc neonatal receptor (FcRn) was originally discovered as

4 Fc receptor function of FCRL4 was demonstrated by bindin

5 Fc receptor-like (FCRL) 4 is an immunoregulatory recepto

6 ion disrupted the binding between the IgG(1) Fc and Fcgamma receptor IIIa, resulting in decreased ADC

7 Using Me(10)Fc(+), a 1 2 equilibrium was established, allowing for c

8 Quantitative data on 12 Fc-glycosylation features of 23 mAb-Ds (12 clones, 5 pro

9 blocking of 4-1BBL signaling by Ab or 4-1BB-Fc alleviated the pathology of psoriasis by regulating t

10 Growth factor sequestration by IGFBP-3-Fc enhances the activity of EGFR inhibitors by decreasin

11 f tumor growth in vivo with adjuvant IGFBP-3-Fc with erlotinib versus erlotinib after treatment cessa

12 sion of CD11c, low levels of CD21, FcRL 1-5 (Fc receptor-like protein 1-5) expression, and, in some c

13 mmunoglobulin G1 (IgG1) versus those given a Fc-Null variant of the same antibody.

14 ng activities of various antibodies and ACE2-Fc soluble decoy protein in both assays revealed a high

15 However, Abs that activate Fc gama receptors (FcgammaRs) and mediate antibody-depen

16 tly nonneutralizing antibodies that activate Fc receptors and bind complement, and a glycoprotein D s

17 ntibodies functioned primarily by activating Fc receptors to mediate antibody-dependent cellular cyto

18 , we found that the rapid loss of activating Fc receptors from the surface and their subsequent prote

19 creased likelihood of IgG1 with afucosylated Fc glycans.

20 We further developed an Fc-engineered mutant version of omalizumab, and demonstr

21 Therefore, we developed an Fc-modified KKO that does not induce these negative outc

22 ement in performance was demonstrated for an Fc-fusion protein therapeutic.

23 oth muscle cell proliferation in vitro in an Fc receptor-dependent manner, and antibody-deficient mic

24 FcgammaRIIb is an Fc receptor that inhibits B cell activation and, if defe

25 Tafasitamab (MOR208) is an Fc-enhanced, humanised, anti-CD19 monoclonal antibody th

26 titumour activity with the combination of an Fc-optimised anti-HER2 agent (margetuximab) along with a

27 rolled, double-blind trial of teplizumab (an Fc receptor-nonbinding anti-CD3 monoclonal antibody) inv

28 ed to present two different VHHs fused to an Fc domain were further shown to be effective upon therap

29 vitro studies of RRV vCD200 have utilized an Fc fusion protein to examine functionality, which does n

30 activity, whereas IgG-containing ICs with an Fc engineered to be unable to engage FcRn did not.

31 of agarose microbeads functionalized with an Fc-binding domain.

32 se (IdeS) cleaves human IgG into F(ab')2 and Fc fragments, potentially inhibiting ADCC.

33 the unfolding patterns of the F(ab')(2) and Fc domains were simultaneously analyzed in a single run

34 lass domain assignments to the F(ab')(2) and Fc regions.

35 or (TCR), B cell antigen receptor (BCR), and Fc receptors uses the same schematic and similar molecul

36 nied by compromised Fcy receptor binding and Fc effector activity, pointing to deficient humoral deve

37 agD-2 had significantly more C1q binding and Fc gamma receptor activation, a surrogate for ADCC funct

38 ction was a result of both heme-blocking and Fc-mediated effector functions, underscoring the importa

39 the coordinated function of both the Fab and Fc domains(1).

40 tibody type and site of conjugation (Fab and Fc) in preclinical studies.

41 with Pf-specific immunoglobulin G (IgG) and Fc receptor activation to control parasitemia.

42 ycan cap epitope, possessed neutralizing and Fc-mediated effector function activities, and potentiate

43 anti-ASNase IgG, antigen:antibody ratio, and Fc-gammaRIII.

44 acquired antigens via convalescent serum and Fc receptors.

45 ences in antibody subclass, specificity, and Fc receptor ligation using pseudovirus entry and multipl

46 y features, with combined PPD IgG titers and Fc domain glycans providing the highest classification a

47 electrons and holes between C(60), ZnP, and Fc is novel.

48 A peptide that blocks antibody Fc-Fc interaction inhibited CDC induced by AQP4 rAbs and

49 ll expansion was independent of the antibody Fc region.

50 Our data suggest that the antibody/Fc-receptor complex functionally mimics viral receptor i

51 , infusion of recombinant therapeutics, ApoM-Fc fusion protein enhanced kidney and lung regeneration

52 ike neutralizing antibody titers, as well as Fc-mediated functional antibody responses, including ant

53 Ab or those with either reduced or augmented Fc function.

54 ntinib or an ultra-high affinity soluble AXL Fc fusion decoy receptor (sAXL) reduced the growth of a

55 ng is due to noncovalent association between Fc regions of neighboring antibodies, resulting in enhan

56 s erythematosus (SLE), these antibodies bind Fc receptors on myeloid cells and induce proinflammatory

57 oy Fcgamma receptor (FcgammaR), which blocks Fc-mediated effector functions, such as Ab-dependent cel

58 ormed on bulk non-antigen-specific IgG, bulk Fc domain, bulk Fab domain, and purified protein derivat

59 ty and Ab-dependent cellular phagocytosis by Fc interactions with FcgammaRs and complement-dependent

60 the immune system, which could be rescued by Fc receptor-dependent Ab opsonization.

61 ate transplacental IgG transport, as certain Fc glycoforms were reported to be enriched in fetal circ

62 extracellular CHL1 domain fused to Fc (CHL1-Fc).

63 Direct binding of CHL1-Fc to the first extracellular loop of DRD2 was shown by

64 IgE possess a very high affinity for cognate Fc receptors expressed by tumor-associated macrophages (

65 Ia; when incorporated into immune complexes, Fc afucosylation enhanced production of inflammatory cyt

66 The ferrocene-acyclovir conjugate Fc-5 featured the highest apparent binding constant valu

67 sing eight repeated fragment crystallizable (Fc) binding domains of streptococcal protein G to a line

68 binding of the IgG fragment crystallizable (Fc) domain to the human neonatal Fc receptor (hFcRn).

69 ity through binding fragment crystallizable (Fc) gamma-receptors (FcgammaRs).

70 inding and neonatal fragment crystallizable (Fc) receptor (FcRn) binding demonstrated no difference b

71 The neonatal fragment crystallizable (Fc) receptor (FcRn) functions as a recycling mechanism t

72 ssed the inhibitory fragment crystallizable (Fc) receptor FcgammaRIIB following activation and multip

73 r functions via the fragment crystallizable (Fc) region, such as interacting with human complement pr

74 sed on human IgG(1)-fragment crystallizable (Fc).

75 mune protection is mediated by the cytosolic Fc receptor and E3 ubiquitin ligase TRIM21.

76 n Ldlrad3, and administration of LDLRAD3(D1)-Fc abolishes disease caused by several subtypes of VEEV,

77 h anti-LDLRAD3 antibodies and an LDLRAD3(D1)-Fc fusion protein block VEEV infection in cell culture.

78 zed MAb dosages in viral-receptor-dependent, Fc-receptor-dependent, and both-receptors-dependent vira

79 For example, we describe Fc mutants that potently disrupted influenza B-mediated

80 These measurements show the direct Fc-electrode coupling provides highly efficient molecula

81 Engineered Fc domains that confer a longer circulation half-life by

82 Finally, an engineered Fc-R2 protein acts as an FGF23 antagonist offering new p

83 novirus immune complexes with the engineered Fc induced greater maturation of human dendritic cells (

84 For example, Fc domain sialylation triggers conformational changes of

85 nformation of IgE, which retains a rigid Fab-Fc architecture.

86 c peptide substrates containing a ferrocene (Fc) tag.

87 During activation, ferrocene (Fc) in PVF is oxidized to the ferrocenium ion (Fc(+)) wi

88 itions a secondary electron-donor ferrocene (Fc, donor(2)) and the primary electron-acceptor C(60)-fu

89 Our data suggests a role for Fc-dependent antibody effector functions in RTS,S-induce

90 uman immunoglobulin crystallizable fragment (Fc) domain for increased stabilization and avidity, the

91 he antibody-binding crystallizable fragment (Fc) gamma receptors (FcgammaRs) are expressed by leukocy

92 that a rarely seen crystallizable fragment (Fc) modification, N325 deamidation, exhibited a positive

93 C7-Ximab) with a complement-enhancing E-to-G Fc mutation at position 430 (2C7-Ximab-E430G).

94 domain fused to rFVIII via immunoglobulin-G1 Fc domains and 2 XTEN polypeptides (Amunix Pharmaceutica

95 The potent neutralization activity of V(H)-Fc ab8 combined with good developability properties and

96 V(H)-Fc ab8 did not aggregate and did not bind to 5,300 human

97 Bivalent V(H), V(H)-Fc ab8, bound with high avidity to membrane-associated S

98 gated at different sites (LC, HC-Fab, and HC-Fc) with various classes of payload-linkers.

99 prising an scFv and a Fab on a heterodimeric Fc eliminates the possibility of light chain mispairing.

100 Multivariate modeling highlighted Fc domain glycan species as the top discriminatory featu

101 Human Fc receptor binding assays and analysis of antibody-cell

102 IV dosing of TXB2 when fused to human Fc domain (TXB2-hFc) at 25 nmol/kg (1.875 mg/kg) in mice

103 s of dimeric, tetrameric, and pentameric IgA-Fc linked by the joining chain (JC) and in complex with

104 omplexes of ligelizumab-Fab with IgE and IgE Fc were assessed by negative stain electron microscopy a

105 parasitic infestation, often mediated by IgE Fc receptor-expressing macrophages.

106 In contrast to the IgE Fc fragment, the IgE Fc in intact IgE is significantly l

107 In contrast to the IgE Fc fragment, the IgE Fc in intact IgE is significantly less asymmetrically be

108 IgG Fc glycans were characterized in 225 healthy children an

109 pseudotyped viruses as a bivalent human IgG Fc-fusion.

110 the spike, and mediates viral entry into IgG Fc receptor-expressing cells through canonical viral-rec

111 ore, previously reported associations of IgG Fc glycosylation with age in healthy individuals were co

112 tes with the presence of proinflammatory IgG Fc structures, including afucosylated IgG1.

113 Meanwhile, MAb binds to cell surface IgG Fc receptor, guiding viral entry through canonical viral

114 The IgG Fc domain has the capacity to interact with diverse type

115 l transport of IgG, we characterized the IgG Fc glycosylation in paired maternal-fetal samples from p

116 ecificity and heterogeneity of the final IgG-Fc glycosylation profile.

117 Manipulation of IgG-Fc/FcRn interactions has implications for treatment of v

118 ding regions of FcgammaRs and C1q on the IgG-Fc largely overlap, IgG1 with a deletion of G236 only si

119 hly conserved N-linked glycan within the IgG-Fc tail, which is essential for IgG function, shows vari

120 d complement-dependent cytotoxicity upon IgG-Fc binding to C1q.

121 TXB2 was fused to a human IgG1 Fc domain (hFc) or to the amyloid-beta (Abeta) antibody

122 -specific VHH antibodies fused to human IgG1 Fc domains based on the epitope predictions for leading

123 -H6-based NK cell engagers with a human IgG1 Fc part competent in Fc receptor binding resulted in an

124 Using mutant human IgG1 Fc regions engineered not to engage complement or FcR-de

125 No differences in IgG1 Fc glycan profiles and minimal differences in IgG2 Fc gl

126 The IgG1 Fc fragments containing complex sialylated glycans attac

127 composition of the immunoglobulin G1 (IgG1) Fc fragment.

128 we compare two panels of glycan-adapted IgG1-Fc mutants expressed in either the human endothelial kid

129 can profiles and minimal differences in IgG2 Fc glycans were noted, whereas the presence or absence o

130 udy, we show that the recombinant human ILT3.Fc protein binds to murine immune cells and inhibits the

131 ther studies on the effect of the human ILT3.Fc protein in murine experimental models of autoimmunity

132 a clinical approach based on the use of ILT3.Fc for treatment of MS.

133 Administration of ILT3.Fc prevents the rapid evolution of the disease in C57BL/

134 N-gamma and IL-17A in mice treated with ILT3.Fc is associated with delayed time of onset of the disea

135 in response to interleukin-22 immunoglobulin Fc (IL22Fc) fusion protein and anti-p40 monoclonal antib

136 a LALA mutant of PGT121 (which has impaired Fc-dependent functions) for their ability to protect pig

137 agers with a human IgG1 Fc part competent in Fc receptor binding resulted in an almost 10-fold superi

138 the V domains modulate FcRn binding site in Fc by allosteric effects.

139 The inserted Fc fragments or antibodies can efficiently activate NK c

140 Besides intracellular Fc receptor function, tripartite motif 21 (TRIM21) E3 li

141 Margetuximab, a novel, investigational, Fc-engineered, anti-HER2 monoclonal antibody, is designe

142 ) in PVF is oxidized to the ferrocenium ion (Fc(+)) with the latter facilitating As(III) sorption and

143 and calcium-dependent target binding and is Fc-engineered to increase affinity at acidic pH to the n

144 y contacted with soluble fluorescein-labeled Fc-binding ligands to produce an immediately-detectable

145 ngs were i) RTS,S-induced antibodies mediate Fc-dependent effector functions, ii) functional antibodi

146 Bournazos et al., 2020) shows that modifying Fc binding affinities to better target FcyRIIa enhances

147 tent stem cells (iPSCs) and used a monomeric Fc-ligand fusion platform to steer the ligand specificit

148 Moreover, Fc gamma receptor genetic variations influenced immune r

149 tion using pseudovirus entry and multiplexed Fc array assays, respectively.

150 Nanobody-Fc fusions showed neutralizing activity against SARS-CoV

151 Neonatal Fc receptor (FcRn) has a key role in the homeostasis of

152 he placenta, dependent on the fetal neonatal Fc receptor (FcRN), and sensitized fetal MCs for allerge

153 tallizable (Fc) domain to the human neonatal Fc receptor (hFcRn).

154 with its cognate cellular recycling neonatal Fc receptor.

155 Silencing neonatal Fc Receptor (FcRn) or CAMK4 prevented the podocyte-damag

156 e types of receptors, including the neonatal Fc receptor (FcRn) and Fcgamma receptors (FcgammaRs), wh

157 The neonatal Fc receptor (FcRn) that mediates IgG and albumin recycli

158 The neonatal Fc receptor (FcRn) transports IgG across barriers, for e

159 d formed a ternary complex with the neonatal Fc receptor (FcRn) under acidic conditions.

160 Here, involvement of the neonatal Fc receptor (FcRn), which mediates IgG recycling and tra

161 some overlap with that seen for the neonatal Fc receptor complexed with enterovirus E6 but is larger

162 Pups used the neonatal Fc receptor to transfer IgG from milk into serum.

163 crease affinity at acidic pH to the neonatal Fc receptor, and to reduce effector functions.

164 A soluble decoy (NgR1-Fc, AXER-204) blocks these ligands and provides a means

165 hicle (n = 6) or 0.10-0.17 mg/kg/day of NgR1-Fc (n = 8) delivered via intrathecal lumbar catheter and

166 hecal and intravenous administration of NgR1-Fc to cynomolgus monkey and to rat are without evident t

167 The data show that NgR1-Fc does not have preclinical toxicological issues in hea

168 The NgR1-Fc group tissue exhibited a significant 2-3-fold increas

169 -specific Abs showed several nonneutralizing Fc-mediated functions, including ADCP and C1q binding.

170 it vaccine that elicits neutralizing but not Fc receptor-activating or complement-binding responses.

171 ouse IgG, which influences IgG activation of Fc receptors, was evaluated by Sambucus nigra lectin blo

172 The high affinity of Fc(+) to As and weak attraction to competing anions at 0

173 Crosslinking of Fc with FcgammaRIIB mediates antibody-dependent enhancem

174 r tyrosine kinase that signals downstream of Fc receptors and plays a transduction role in antibody e

175 Here, the larger reorganization energy of Fc relative to ZnP makes the difference.

176 rus neutralization, whereas Fc engagement of Fc-gamma receptors (FcgammaRs) could mediate an array of

177 ereby maintaining the constant generation of Fc(+) required to achieve As(III) removal in subsequent

178 The impact of Fc engineering on antagonists, however, remains largely

179 However, the investigation of Fc-mediated Ab responses in macaques is complicated by s

180 r the ballistic regime through the number of Fc units able to bridge and the energy position of the f

181 the regeneration step drive the oxidation of Fc to Fc(+), thereby maintaining the constant generation

182 of N-linked glycans between matched pairs of Fc mutants vary greatly and in particular, with respect,

183 ensure the safety and efficacy of IgG(1) or Fc-fusion products.

184 ing the simple outer-sphere Fc(0/+) process (Fc = ferrocene) as a model system, high boiling point (l

185 Antigen specificity, isotype profile, Fc-gamma receptor usage, and complement activation are a

186 entry into cells expressing viral receptor, Fc receptor, or both receptors.

187 ates IgG epithelial transport and recycling, Fc effector activities, such as antibody-dependent cellu

188 low affinity antibody with effector-reduced Fc.

189 -decay kinetics similar to NAbs with reduced Fc function.

190 rus decline between NAb and NAb with reduced Fc function.

191 AAV-RSPO1-Fc-transduced Apc(Min/+) mice also developed fewer and s

192 adeno associated viral vector encoding RSPO1-Fc fusion protein, or control vector, was injected into

193 mice injected with the vector encoding RSPO1-Fc had significantly deeper crypts, longer villi, with i

194 enomas from Apc(Min/+) mice expressing RSPO1-Fc back to the same level as in the adenomas from mice g

195 s of Apc(Min/+) mice injected with the RSPO1-Fc vector showed a rapid increase in apoptosis and in th

196 signaling in organoids stimulated with RSPO1-Fc restored organoid formation and expression of genes r

197 which were incubated with or without RSPO1-Fc and an inhibitor of transforming growth factor beta r

198 his study, we analyzed the potential of sCAR-Fc for treatment of chronic CVB3-induced myocarditis in

199 d 7 after injection and compared with a scFv-Fc control antibody construct targeting glycophorin A.

200 ntibodies were further characterized as scFv-Fc with 35 produced as fully human IgG1.

201 ng from a monovalent scFv to a bivalent scFv-Fc format improved its binding affinity toward native CD

202 Fv-CD44 was reformatted into a bivalent scFv-Fc-CD44, based on human IgG(1)-fragment crystallizable (

203 -Fc-CD44 when compared with the control scFv-Fc.

204 linical investigation of [(89)Zr]Zr-DFO-scFv-Fc-CD44 as a versatile PET imaging agent for patients wi

205 umor-to-blood ratios for [(89)Zr]Zr-DFO-scFv-Fc-CD44 between days 5 and 7.

206 aging was conducted with [(89)Zr]Zr-DFO-scFv-Fc-CD44 on days 1 and 7 after injection and compared wit

207 nt tumor specificity for [(89)Zr]Zr-DFO-scFv-Fc-CD44 when compared with the control scFv-Fc.

208 ]Cu-NOTA-scFv-Fc-CD44 or [(89)Zr]Zr-DFO-scFv-Fc-CD44.

209 e binding arms, particularly in the Fab-scFv-Fc format.

210 neered into two other antibody formats (scFv-Fc and IgG1).

211 imes after injection of [(64)Cu]Cu-NOTA-scFv-Fc-CD44 or [(89)Zr]Zr-DFO-scFv-Fc-CD44.

212 onclusion: We developed a CD44-specific scFv-Fc construct that binds with nanomolar affinity to human

213 The scFv-Fc-CD44 was radiolabeled with (64)Cu and (89)Zr.

214 While C1q binds to a single Fc with low affinity, a higher avidity stable binding of

215 ndividual ebolaviruses, epitope specificity, Fc-mediated functions, and protection against the three

216 Using the simple outer-sphere Fc(0/+) process (Fc = ferrocene) as a model system, high

217 In this study, Fc-mediated effector functions have been quantified in v

218 antibodies (mAbs) expressing an IgG subtype Fc-domain were selected for further expansion and purifi

219 in IgG transplacental transport, suggesting Fc engineering of maternally administered antibody to en

220 mine ligand was systematically synthesized ((Fc(2)PDI)MCl(2), M = Mg, Zn, Fe, and Co) and characteriz

221 Similarly, a murine TGFBRII-Fc ligand trap administered after injury significantly r

222 through inhibition of viral entry, but that Fc function can contribute to the overall antiviral acti

223 by engaging FcgammaRs, and demonstrate that Fc-engineered versions of the mAb could be used to reduc

224 ns of the observed differences indicate that Fc-mediated effector functions accounted for 25-45% of t

225 Here we report that Fc engineering of anti-influenza IgG monoclonal antibodi

226 The Fc domain engages a wide spectrum of receptors on discre

227 The Fc units were directly coupled to the electrodes, i.e.,

228 ithout chemical anchoring groups between the Fc units and the terminal electrodes.

229 The protection was mediated by the Fc fragment functions of MR228.

230 This process is facilitated by the Fc receptor CD16a on human NK cells.

231 (TF-CAR-NK) cells that co-express CD16, the Fc receptor (FcgammaIII) to mediate antibody-dependent c

232 we used systems serology to characterize the Fc profile of influenza-, pertussis-, and SARS-CoV-2-spe

233 drug molecule allows to rapidly confirm the Fc-drug conjugation at the chromatographic level.

234 However, the Fc portion of this antibody activates the immune respons

235 ng elucidated, with one theory involving the Fc region of antibodies.

236 tor binding and functional properties of the Fc are lost after deglycosylation or removal of the uniq

237 measurements for 77 peptide sequences of the Fc fragment.

238 The relative sialylation of the Fc glycan on mouse IgG, which influences IgG activation

239 elevated binding to the G0 glycoform of the Fc portion of IgG.

240 d that lung cDC2s acquired expression of the Fc receptor CD64 shared with MCs and of IRF8 shared with

241 Glycosylation of the Fc region of alpha-GA(1) is important for cell entry and

242 FT-IR confirmed the formation of the Fc-GO nanocomposite and PEI deposition on the electrode

243 l glycosylation occurs preferentially on the Fc domain, providing significant discriminatory power be

244 o enhanced differential glycosylation on the Fc domain.

245 the presence or absence of galactose on the Fc glycan of IgG1 did not alter FcgammaRIIIa or FcRn bin

246 (CDRs), as well as N-glycans present on the Fc/2 fragment, to be monitored with similar sensitivity

247 ated by introducing the LALA mutation to the Fc region (MW05/LALA).

248 valently linked with enzymes and bind to the Fc region of target-bound primary antibodies to amplify

249 served N-linked carbohydrate attached to the Fc whose presence and fine structure profoundly impacts

250 the distal Fabs are rigidly tethered to the Fc.

251 ng that the IgE Fab is fixed relative to the Fc.

252 ich-type immunoreaction was achieved via the Fc-specific FITC@SiO(2)-NH(2)-anti-IgG binding to the ca

253 In therapeutic applications in which the Fc of IgG is critically important, the receptor binding

254 nd immunoglobulins bind to C1q through their Fc region.

255 This Fc modification on severe acute respiratory syndrome cor

256 visualize lung macrophages activated through Fc receptors by antibody-coated glass slides.

257 ibodies for their increased activity through Fc receptors (FcgammaRIIIa).

258 ate the loss of virus-infected cells through Fc gamma receptor (FcgammaR)-mediated effector functions

259 arance in vivo in preclinical models through Fc-FcgammaR interactions.

260 hrough endosomal Toll-like receptors (TLRs), Fc gamma receptors (FcgammaR), and antigen receptors in

261 tic monoclonal antibodies require binding to Fc gamma receptors (FcgammaRs) for full effect and incre

262 generation step drive the oxidation of Fc to Fc(+), thereby maintaining the constant generation of Fc

263 combinant extracellular CHL1 domain fused to Fc (CHL1-Fc).

264 ed on two GCSF-receptor sites immobilized to Fc domains, which are common parts of protein structures

265 hieved at -1.2 V wherein Fc(+) is reduced to Fc thereby facilitating As desorption from the electrode

266 a two-step enzymatic procedure to transform Fc-glycans present on IgG mAbs into two site-specific an

267 h 7S IgY and 5.7S IgY, which has a truncated Fc region.

268 Ultimately, Fc engineering of human glycan-targeting IgG1 mAb confer

269 s (DC) than immune complexes with unmodified Fc and stimulated increased Ag-specific CD8 T cell proli

270 nT, or GalNAc-LNnT) as 2C7-Ximab (unmodified Fc).

271 en that most solid tumor antibodies that use Fc-dependent mechanisms or radioimmunotargeting have lar

272 ups onto three lysine residues in IgGs using Fc affinity peptide reagents without antibody engineerin

273 bs were found to be neutralizing, to utilize Fc effector functions, and to be protective against leth

274 torage protein cruciferin with that of a VHH-Fc antibody without endogenous target.

275 f a seed-expressed nanobody-heavy chain (VHH-Fc) antibody against the highly abundant Arabidopsis tha

276 Nanobody-heavy chain (VHH-Fc) antibody formats have the potential to immunomodulat

277 The resulting tri-specific VHH-Fc antibodies show more potent S1 binding, S1/ACE2 block

278 s and interact with CD68(+) immune cells via Fc receptors.

279 0) under unmediated conditions to -1.07 V vs Fc(+/0) in the presence of phenols.

280 onset potential of catalysis from -0.65 V vs Fc(+/0) under unmediated conditions to -1.07 V vs Fc(+/0

281 of high redox potential (E(1/2) = +1.19 V vs Fc(+/0)) and charge-discharge cycling stability (with 92

282 ivatives will range from +0.96 to +1.64 V vs Fc(+/0), depending upon the substituents on the benzene

283 f the reduction potential of S as -1.17 V vs Fc(+/0).

284 ction potential of 1 as -0.525 +/- 0.01 V vs Fc(+/0).

285 ts the most positive V(FB) value (-0.02 V vs Fc/Fc(+)) by a wide margin.

286 ydrogen evolution reaction (HER) (-0.55 V vs Fc/Fc(+)) compared to other substrates herein.

287 could mediate virus neutralization, whereas Fc engagement of Fc-gamma receptors (FcgammaRs) could me

288 the electrode is achieved at -1.2 V wherein Fc(+) is reduced to Fc thereby facilitating As desorptio

289 Parallel profiling of whole, Fc, and Fab domain-specific IgG glycosylation pointed to

290 ce of serial dilutions of anti-CD20 Abs with Fc domains corresponding to each of the four subclasses

291 ibody binding to cell-surface NS1 along with Fc effector functions engagement correlate with protecti

292 subclasses of human and rhesus IgG and with Fc variants of IgG1 that enhance binding to FcgammaR2A o

293 was observed when the Del was combined with Fc mutations improving FcRn binding (Del-FcRn(+)).

294 for example, the adjacent C(60)(*-)-ZnP(*+)-Fc charge-separated state is located in the inverted reg

295 ntermediate in addition to C(60)(*-)-ZnP(*+)-Fc, en route to the distant C(60)(*-)-ZnP-Fc(*+) charge-

296 cent charge-transfer states, a C(60)-ZnP(*-)-Fc(*+) intermediate in addition to C(60)(*-)-ZnP(*+)-Fc,

297 ion, while that of the distant C(60)(*-)-ZnP-Fc(*+) charge-separated state lies in the normal region.

298 +)-Fc, en route to the distant C(60)(*-)-ZnP-Fc(*+) charge-separated state.

299 erating distant and long-lived C(60)(*-)-ZnP-Fc(*+) charge-separated states.

300 e bridges as a function of C(60)-ZnP and ZnP-Fc distances is decisive in the context of generating di